Loading resources...
§ Grant
Funds ALS research for academic researchers, clinicians, and biotech startups, from basic science to clinical trials.
Grants range from $50,000 for exploratory projects to over $1 million for multi-year clinical research initiatives.
Academic researchers, clinical investigators, and biotech startups developing ALS therapeutics, diagnostics, and assistive technologies.
Yes, all grants are non-dilutive. The ALS Association does not take equity in funded organizations.
The program funds basic science, translational research, clinical trials, and assistive technology development for ALS patients.
The Association publishes requests for proposals on its website with specific deadlines for each funding cycle throughout the year.
The ALS Association Research Grants are a series of funding programs administered by the ALS Association to support scientific investigation across the translational pipeline from basic science to early-phase clinical trials. The organization currently maintains a portfolio of over 100 active grants distributed through specific mechanisms with varying financial parameters. Funding categories include $50,000 Seed Grants for critical experiments, the Lawrence and Isabel Barnett Drug Development Program offering up to $500,000, and Hoffman ALS Clinical Trial Awards providing $1 million or more. Application deadlines align with specific Request for Applications cycles, and certain awards involve partnerships with recognizable entities like the American Brain Foundation, the American Academy of Neurology, and Target ALS. This resource is intended for academic researchers, clinical investigators, and biotech startups seeking non-dilutive funding to develop therapeutics, disease models, diagnostics, and assistive technologies.
The ALS Association Research Grants program is a non-dilutive funding initiative supporting research into amyotrophic lateral sclerosis treatments, diagnostics, and assistive technologies. Awards range from $50,000 to over $1 million, targeting academic researchers, clinical investigators, and biotech startups working to understand, treat, and ultimately cure ALS.
Academic researchers, clinical investigators, and biotech startups developing ALS therapeutics, diagnostics, and assistive technologies are eligible. Proposals must focus specifically on ALS-related research, including basic science, translational research, clinical trials, and technology development for patient care. Both established investigators and early-career researchers are encouraged to apply.
Grants range from $50,000 for smaller exploratory projects to over $1 million for multi-year clinical research initiatives. Funded researchers gain access to the ALS Association's network of clinical sites, patient registries, and biorepositories. The organization also facilitates connections between funded researchers to encourage collaboration and accelerate the pace of discovery.
The ALS Association publishes requests for proposals on its website, with specific deadlines for each funding cycle. Applications undergo peer review by scientific advisory committees. Proposals should detail the research plan, expected outcomes, budget, and relevance to ALS treatment or patient care advancement.
The ALS Association has invested over $130 million in research since its founding, funding groundbreaking work in gene therapy, biomarker development, and clinical trial infrastructure. The organization played a key role in advancing several ALS therapeutics through its research pipeline funding.